Clinical trial NCT05643170: An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Official title: A Multi-center, Open-label Study to Assess the Effectiveness, Long-term Safety, Tolerability, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Schizophrenia
Lead sponsor: Karuna Therapeutics
Sponsor class: INDUSTRY
First posted: 2022-12-08
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be switched to receive KarXT.

The primary objectives of the study are to assess the long-term safety and tolerability of KarXT and assess effectiveness, persistence, and durability of effect of KarXT through the Investigator Assessment Questionnaire (IAQ) and Clinical Global Impression - Severity of Illness (CGI-S) scale in patients with a diagnosis of schizophrenia.

The secondary objectives are to further assess the effectiveness using the Clinical Global Impression, Global Improvement (CGI-I), long-term safety and tolerability of KarXT, and evaluation of scores from multiple additional patient scales and assessments throughout the study.


Eligibility criteria: Inclusion Criteria:

1. Patient is aged 18 to 65 years, inclusive, at screening.
2. Patient can provide informed consent.

   1. A signed informed consent form (ICF) must be provided before any study assessments are performed.
   2. Patient must be fluent (oral and written) in the language of the ICF to consent.
3. Patient has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM 5 (American Psychiatric Association, 2013) criteria and has been in the continuous care of the clinician or practice for at least 6 months prior to entering the study.
4. The patient is dissatisfied with the side effects or general tolerability of their current antipsychotic medication, and for this reason, desires to change medications. Or, the patient is dissatisfied with the overall effectiveness or benefit of their current antipsychotic medication, and for this reason, desires to change medications.
5. The patient has not required psychiatric hospitalization, acute crisis intervention, or other increase in their level of care due to symptom exacerbation within 4 weeks of screening, and in the opinion of the investigator, is psychiatrically stable to be managed in an outpatient setting.
6. The patient has a CGI-S score of ≤4 (moderately severe or less) at screening and baseline visits.
7. For at least 30 days prior to screening, the patient must have been prescribed and have taken an oral antipsychotic medication daily at a dose and frequency consistent with the drug label.
8. Patient has an identified, reliable caregiver/informant that is willing (by informed consent) and able to respond to the ZBI 22 caregiver burden scale at specified visits. If the patient has been the patient of the investigator for ≥6 months and, in the opinion of the investigator, the patient is self-sufficient, then a caregiver/informant may not be necessary.
9. Patient resides in a stable living situation and is anticipated to remain in a stable living situation for the duration of the study, in the opinion of the investigator.
10. If a woman of childbearing potential (WOCBP) or a man whose sexual partner(s) is a WOCBP, the patient must be willing and able to adhere to the contraception guidelines as defined in Section 12.1 Appendix 1.

Exclusion Criteria:

1. Any primary DSM-5 disorder diagnosis other than schizophrenia within 12 months before screening. Exclusionary disorders include, but are not limited to, bipolar I or II disorder and schizoaffective disorder. Symptoms of mild mood dysphoria or anxiety are allowed, as long as these symptoms are not the primary focus of treatment.
2. The patient has a history of or presence of a clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, is likely to jeopardize the safety of the patient or the validity of the study results.
3. Patient has a history of or is at high risk of urinary retention, gastric retention, or narrow angle glaucoma.
4. Patient has a history of irritable bowel syndrome (with or without constipation) or constipation requiring treatment for more than 30 days within the last 6 months.
5. Clinically significant abnormal finding on the physical examination, medical history, electrocardiogram (ECG), or clinical laboratory results at screening.
6. Patient is pregnant, lactating, or less than 3 months postpartum.
7. Patient has tested positive for coronavirus disease 2019 (COVID-19) within 2 weeks of screening and/or baseline or patients who have prolonged symptoms of past infection, long COVID, that, in the opinion of the investigator, may interfere with the interpretation of safety during the study.
8. Patient with extreme concerns relating to global pandemics, such as COVID-19, that precludes study participation.
9. Patient is currently or recently (within 4 weeks of screening) involuntary hospitalization or incarceration.
10. Patient participated in another clinical study in which they received an experimental or investigational drug agent within 30 days prior to screening.

Primary outcomes:
measure: The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation
timeFrame: From first dose to 28 days post last dose (up to approximately 113 days)
measure: Investigator Assessment Questionnaire (IAQ) Scores
timeFrame: At visit 1, 3, 5 (Baseline, week 4, 8), and early termination visit (study day 85)
measure: Clinical Global Impression - Severity of Illness (CGI-S) Scores
timeFrame: At visit 1, 2, 3, 5 (baseline, week 2, 4, 8)
Secondary outcomes:
measure: The Number of Participants With Serious Treatment-Emergent Adverse Events (TESAEs)
timeFrame: From first dose to 28 days post last dose (up to approximately 113 days)
measure: The Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
timeFrame: From first dose to 28 days post last dose (up to approximately 113 days)
measure: Clinical Global Impression - Improvement (CGI-I) Score
timeFrame: At visit 2, 3, 5 (Weeks 2, 4, 8)
measure: Medication Satisfaction Questionnaire (MSQ) Score
timeFrame: Visit 5 (Week 8)
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Advanced Discovery Research, LLC
state: Georgia
city: Louisville
country: United States
facility: Seven Counties Services, Inc.
state: Kentucky
city: Columbus
country: United States
facility: Mid Ohio Behavioral Health
state: Ohio
city: Rock Hill
country: United States
facility: OnSite Clinical Solutions, LLC
state: South Carolina
city: Saint George
country: United States
facility: Integrated Clinical Research
state: Utah
Study officials:
References: